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Abstract
Background: The pathological processes underlying dementia are poorly understood and so are
the markers which identify them. Carnosinase is a dipeptidase found almost exclusively in brain and
serum. Carnosinase and its substrate carnosine have been linked to neuropathophysiological
processes.
Methods: Carnosinase activity was measured by a flourometric method in 37 patients attending a
Geriatric Outpatient Clinic. There were 17 patients without dementia, 13 had Alzheimer's disease
(AD) and 7 had mixed dementia (MD).
Results: The range of serum carnosinase activity for patients without dementia was 14.5 – 78.5
µmol/ml/h. There was no difference in carnosinase activity between patients without dementia
(40.3 ± 15.2 µmol/ml/h) and patients with AD (44.4 ± 12.4 µmol/ml/h) or MD (26.6 ± 15 µmol/ml/
h). However, levels in the MD group were significantly lower than the AD group (p = 0.01). This
difference remained significant after adjusting for gender, MMSE score, exercise, but not age, one
at a time and all combined. The effect of other medical conditions did not remove the significance
between the AD and MD groups. The MD group, but not the AD group, demonstrated a significant
trend with carnosinase activity decreasing with duration of disease (from first recorded date of
diagnosis to date of blood collection) (r = -0.76, p = 0.049). There was no association with
carnosinase activity and MMSE score in the AD or MD group. Both AD and MD patients on any
dementia medication (donepezil, galantamine, memantine) had higher carnosinase activity
compared to those not taking a dementia medication. Carnosinase activity was higher in patients
who regularly exercised (n = 20) compared to those who did not exercise regularly (n = 17)(p =
0.006).
Conclusion: This exploratory study has shown altered activities of the enzyme carnosinase in
patients with dementia.
Background
Dementia has emerged as a major clinical, societal and
economic problem, especially in industrialized societies.
Alzheimer's disease (AD) is the most common form of
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dementia followed by vascular dementia and mixed
dementia (AD with cerebrovascular disease). Early and
accurate diagnosis is desirable, as current therapies are
most effective in the early stages [1]. Early diagnosis also
allows the cognitively aware patient to deal with future
issues in medical care, safety, and legal matters [2].
Numerous plasma and serum markers for dementia have
been identified, and many show significant differences
between patients with dementia and those without
dementia, but they lack the sensitivity and specificity
needed for diagnosis. Furthermore, no biomarker has yet
demonstrated the utility to monitor the progress of the
disease, response to therapy or to predict outcome. Most
of the proposed biomarkers are not brain specific but
reflect other pathologies involving coagulation and
inflammation [3], immunological [4], detoxification [5],
oxidative stress [6], lipid metabolism and vascular disease
[6,7]. Although proteins specific to the neuropathology of
amyloid plaques such as amyloid β-protein (Aβ) and
amyloid precursor protein (APP) are detectable in periph-
eral blood, they have shown little value in diagnosis or
monitoring therapy [6].
Successful markers of dementia will most likely be linked
to pathological processes within affected brain cells. Car-
nosinase (CN1; EC 3.4.13.20) is an enzyme found almost
exclusively in brain tissue and serum [8]. It is a member of
the M20 metalloproteinase family and specifically
degrades dipeptides. Two of these, carnosine (β-alanyl-
histidine) and homocarnosine (γ-aminobutyryl-histi-
dine), have been linked to aging and dementia.
Carnosine has many reported functions including intrac-
ellular buffer, metal- chelator (particularly copper), anti-
oxidant, and free radical scavenger [9]. It reacts with pro-
tein carbonyl groups serving as an alternative to glucose,
reversing the glycation process at the Schiff base stage
[10]. Carnosine, through its copper chelating and anti-gly-
cating function, inhibits the production of advanced gly-
cation endproducts (AGEs) [11]. AGEs result from the
reaction of amino groups with reducing sugars resulting in
irreversibly cross-link proteins. While AGEs are consid-
ered part of the normal aging process [12], accelerated
production is implicated in the formation of β-amyloid
plaques and neurofibrillary tangles [11]. Carnosine may
also serve as an anti-senescence agent since it has been
shown to extend the life of human diploid fibroblasts [13]
and reduce the rate for telomeric shortening and damage
to DNA of human fetal lung fibroblasts [14].
In the olfactory bulb, carnosine prevents the inhibitory
effects of copper on synaptic transmission through chela-
tion, thus acting as a neuromodulator [15]. Since AD is
characterized by early changes in the olfactory system [16]
and high levels of copper are associated with senile
plaques and neurofibrillary tangles [17], lower levels of
carnosine could decrease copper chelation and impair
olfaction through decreased synaptic transmission [15]
and neurotoxic effects [18].
Homocarnosine, a specific substrate of carnosinase is
degraded into γ-aminobutyric acid (GABA) and L-histi-
dine. Post-mortem and imaging studies of AD have
shown decreases in GABA in the temporal, frontal, and
parietal regions [19]. Decreased histidine levels in the
frontal and temporal lobes of AD patients have also been
reported [20]. Since histidine is produced when carnosine
and homocarnosine is cleaved by carnosinase, this obser-
vation may reflect decreased carnosinase activity.
Case studies of carnosinase deficiency have reported
symptoms that include progressive mental deficiency,
non-progressive mental retardation, developmental
delay, spastic paraplegia, seizures, neurosensory hearing
loss, retinitis pigmentosa, and progressive childhood
dementia [21,22]. Reduced activity levels have been
found in other neurological disorders including Parkin-
son's disease, multiple sclerosis, and following a cerebrov-
ascular event [23,24]. Recently, serum carnosinase levels
have been shown to decrease during cardiopulmonary
bypass surgery [25]. Ischemia is a major complication of
cardiac surgery and a decrease in carnosinase during this
procedure may be a neuroprotective mechanism [25] as
carnosine may reduce neurotoxicity through its antioxi-
dant capacity [18]. Brains afflicted with AD show bio-
chemical evidence of ischemia, specifically Aβ deposits
and an increase in basic fibroblastic growth factor [26].
Decreased blood flow and oxygenation has been docu-
mented in the temporal lobes in AD [27]. These vascular
changes may initiate the same decrease in carnosinase
activity as seen in patients with cerebrovascular events.
Carnosine has also been shown to produce vascular relax-
ation whereas its constituent amino acid β-alanine pro-
duced vasoconstriction [28].
In light of this growing body of information relating car-
nosinase and its substrates to dementia, we undertook an
exploratory study to investigate carnosinase activity in
patients with dementia.
Methods
Participants
After approval by the Hamilton Health Sciences/McMas-
ter Faculty of Health Sciences Research Ethics Board, we
studied 37 patients who attended a Geriatric Outpatient
Clinic at Hamilton Health Sciences between July 2004
and April 2005. Informed consent was obtained from the
patient or relative. A questionnaire was administered to
patients collecting data about their family history of disor-BMC Neurology 2007, 7:38 http://www.biomedcentral.com/1471-2377/7/38
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ders, diet, exercise frequency, and recent weight loss. All
prescriptions, over-the-counter medications and supple-
ments were recorded. Medical history was obtained and
confirmed through medical records. The most recent
mini-mental state examination (MMSE) score was used as
a global measure of cognition [29]. The diagnosis of
dementia was based upon the NINCDS-ADRDA criteria
[30] incorporating clinical assessment, laboratory and
neuroimaging studies where indicated.
Carnosinase activity
Blood samples were collected by venipuncture. Serum was
separated after samples were centrifuged at 2,000 × g for
10 min at room temperature, aliquoted and stored at -
20°C until analysis. Serum carnosinase activity was
assayed by the method described by Lenney et al. [31]. All
reagents were purchased from Sigma-Aldrich Canada Ltd.
(Oakville, ON). Serum (50 µl) was first incubated at 30°C
with 250 µl NH4OH (pH 8.5) and 150 µl CdCl for 10
min. The enzyme reaction was started by adding 100 µl of
100 mM carnosine and allowed to proceed for 30 min at
30°C. At this point the reaction was stopped by adding
500 µl of 0.6 M TCA. The solution was centrifuged 800 ×
g for 10 min and the supernatant removed. L-Histidine
was measured fluorometrically by the method described
by Ambrose et al. [32]. Briefly, 50 µl of supernatant was
combined with 1.2 ml 0.83 N NaOH and 500 µl 0.2% o-
phthalaldehyde (OPA) and incubated at 30°C for 15 min.
The reaction was stopped by adding 500 µl 4.0 M H3PO4
and incubated for a further 15 min at 30°C. The solution
was cooled at room temperature for 1 hour and read on a
SpectraMax M2 spectrophotofluorometer (Molecular
Devices, Sunnyvale, CA) at an excitation wavelength of
340 nm and emission wavelength of 450 nm.
Standard curves and detection limits
Standard curves were created using L-histidine and water
in place of TCA supernatant in the o-phthalaldehyde
assay. Standard curves using combinations of carnosine,
β-alanine, and L-histidine representing different levels of
hydrolysis were not significantly different from standard
curves with L-histidine and water [33]. Carnosinase activ-
ity was calculated using the L-histidine standard curve and
was expressed as µmol of L-histidine produced per ml of
serum per hour. The lowest limit of detection was deter-
mined by adding 3 SD to the mean fluorescence of 20
blank replicates, which corresponded to an enzyme activ-
ity of 4 µmol/ml/h.
Statistical analysis
Normal distribution of the data was done using the Kol-
mogorov-Smirnov test and Shapiro-Wilk tests. The Pear-
son correlation was calculated for relationships among
serum carnosinase activity, duration of dementia and
MMSE score. The software used for these analyses was
Analyze-it for Microsoft Excel (Analyze-it Software, Ltd.,
Leeds, England). Group comparisons were performed
using the student's t-test, regression analysis and analysis
of variance (SPSS 12.0, SPSS Inc., Chicago, IL). Compari-
sons were considered to be significant when p < 0.05.
Results
The study population consisted of 17 patients without
dementia and 20 patients with dementia. The dementia
group included 13 patients with AD and 7 patients with
MD. There were more females (n = 29) than males (n = 8)
in all groups. There were no significant differences in age
between any groups (p > 0.05). Demographic and clinical
characteristic data are presented in Table 1.
Carnosinase activity for patients without dementia was
14.5 – 78.5 µmol/ml/h, comparable to the adult range
determined by Lenney et al. (18 – 72 µmol/ml/h) using
the same method [31]. The results of the analysis of vari-
ance showed a significant difference in means across
groups (p = 0.04). Further analysis showed there was no
difference in carnosinase activity between patients with-
out dementia (40.3 ± 15.2 µmol/ml/h) and patients with
AD (44.4 ± 12.4 µmol/ml/h) or MD (26.6 ± 15 µmol/ml/
h) (Figure 1). However, the difference between the AD
and MD groups was significant (mean difference = 17.8
µmol/ml/h, p = 0.01).
Table 2 shows the pairwise comparisons after adjusting
for age, gender, MMSE score and exercise (one variable at
a time and all variables combined). The results show there
was a significant difference in the means of carnosinase
between AD and MD groups after adjusting for each vari-
able except for age (p = 0.06). The effect of medical condi-
tions, other than dementia on carnosinase activity, was
tested by comparison of groups (unpaired t-test) after
removal of each medical condition listed in Table 1. Table
3 shows that the AD group remains significantly different
(p < 0.05) from the MD group regardless of which medical
condition is removed.
Further analysis of the MD group demonstrated a signifi-
cant trend with carnosinase activity decreasing with dura-
tion of disease (from first recorded date of diagnosis to
date of blood collection) (r = -0.76, p = 0.05) (Figure 2).
There was a positive association with carnosinase activity
and MMSE scores, although not significant (r = 0.55, p =
0.21) (Figure 3). There was no significant association in
the AD group between carnosinase activity and duration
of disease (r = -0.06, p = 0.86) or with MMSE score (r = -
0.19, p = 0.54). Diet containing meat, a source of carnos-
ine, or use of dementia medications (donepezil, galan-
tamine, memantine) was not associated with a difference
in carnosinase activity between patients with dementia
(AD and MD) and those without dementia (p > 0.05).BMC Neurology 2007, 7:38 http://www.biomedcentral.com/1471-2377/7/38
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However, carnosinase values were higher in both AD and
MD for the patients on dementia medications compared
to those who were not on dementia medications. Signifi-
cance between groups was reached for AD (p = 0.05), but
not for MD (p = 0.59). Diet containing meat did not show
a difference within the AD or MD groups. Exercise on the
day of blood collection showed no difference between
patients with dementia and those without dementia, but
exercising three or more times a week was associated with
an increase in carnosinase activity (n = 37, p = 0.006) (Fig-
ure 4).
Discussion
In this study we have shown that levels of carnosinase
activity have the potential to differentiate AD from MD
with very little overlap between these conditions. As the
only known difference between these groups was the pres-
ence or absence of cerebrovascular disease, this suggests
that vascular pathology may be the reason for lower car-
nosinase activity. Vascular dementia is associated with cer-
ebrovascular accident, a condition known to lower
carnosinase activity [23,24]. Furthermore, compared to
patients without dementia, carnosinase activity remains
significantly decreased three months after a cerebrovascu-
lar accident [23]. Decreased levels have also been found in
Box-and-whisker plot showing carnosinase activity in without  dementia (n = 17), AD (n = 13), and MD (n = 7) groups Figure 1
Box-and-whisker plot showing carnosinase activity in 
without dementia (n = 17), AD (n = 13), and MD (n = 
7) groups. Comparisons were not significant between with-
out dementia and AD or MD groups, however the difference 
between the AD and MD groups was significant (p = 0.01).
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Table 1: Demographic and clinical characteristics of the without dementia, AD and MD groups. AD, Alzheimer's disease; MD, mixed 
dementia
Patient group
Without dementia AD MD
Number of patients 17 13 7
Mean age (range) 80.2 (64–92) 75.5 (58–88) 82.3(72–92)
Female gender 15 8 6
Mean aterial pressure (mmHg) 99 ± 13 103 ± 9 97 ± 7
Duration of dementia (month) - 19 ± 18 11 ± 10
Mini-mental state examination (MMSE) score - 20 ± 7 21 ± 7
Neuroimaging (CT or MRI) 2 5 4
Diet, meat eaten within the last day 13 11 4
Exercise, 3 or more times per week 9 9 2
Medical Conditions:
Arthritis 8 4 4
Cardiovascular disease 5 4 3
Depression 4 2 2
Diabetes 3 1 1
Hypothyroidism, treated 2 1 0
Parkinson's disease 1 0 0
Renal insufficiency 0 0 2
Stroke, history 2 0 0
TIA, history 0 1 2
Dementia medication:
Donepezil 0 6 2
Memantine 0 1 0
Galantamine 0 1 2
AD, Alzheimer's disease; MD, mixed dementia.BMC Neurology 2007, 7:38 http://www.biomedcentral.com/1471-2377/7/38
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Parkinson's disease [24]. In an autopsy series of over 700
Parkinsonism patients, 19% had co-existing cerebrovascu-
lar lesions, and 20% of secondary Parkinsonism patients
had vascular lesions [34]. Our current findings allow spec-
ulation that carnosinase could differentiate "pure" AD
from vascular dementia, which cannot be achieved with
either CSF Aβ1–42 or CSF total tau [1]. Further evidence
supporting a vascular role for carnosinase comes from a
recent study showing that its substrate carnosine causes
vascular relaxation independent of the endothelium [28].
Several reasons have been suggested for decreased carnos-
inase levels in neurological disorders. Wassif et al. [24]
suggested that a disruption of the blood brain barrier
(BBB) could result in reduced activity of carnosinase seen
in several disorders of the CNS. This idea is supported by
the ability of cerebral ischemia to alter the BBB, specifi-
cally changing endothelial permeability and basal lamina
integrity [35]. The association of multiple sclerosis with
BBB hyperpermeability further supports this idea [36,37].
Skoog [37] found higher CSF/serum albumin ratios in
several types of dementia including AD and vascular
dementia indicating an impairment of the BBB. Recently,
aggregation of Aβ has been associated with damage to the
structural microvascular and BBB abnormalities in an AD
mouse model [38]. Damage to carnosinase-producing
cells could be another reason for reduced carnosinase
activity. In stroke patients, Butterworth et al. [23] found
no relationship between size of the infarct and carnosi-
nase activity. If death of carnosinase producing cells were
responsible one would expect more cell death to cause a
greater decrease in carnosinase activity.
Schoen [25] suggested that the decreased levels of carnos-
inase seen during cardiopulmonary bypass surgery were
protective as both carnosine and homocarnosine can pro-
tect neurons against ischemia and oxidative stress. On the
other hand, carnosinase degrades homocarnosine to
GABA, an inhibitory neurotransmitter. Lower GABA levels
may lead to increased neuronal damage and death. In one
study of patients who had suffered a stroke, lower carnos-
inase activity was correlated with poorer outcome [23].
Table 3: Mean carnosinase activity in the without dementia, AD and MD groups after removal of medical conditions (Table 1)
Medical condition removed Carnosinase (µmol/ml/h)
Without dementia AD MD
None 40.3 44.4 26.6**
Arthritis 35.8 47.0 22.0*
Cardiovascular disease 41.2 41.6 21.4*
Depression 41.5 44.5 26.2*
Diabetes 36.6 44.5 28.7*
Hypothyroidism, treated 40.3 42.6 26.6*
Parkinson's Disease 38.9 44.4 26.6**
Renal insufficiency 39.0 44.4 27.6*
Stroke, history 40.3 44.4 26.6**
TIA, history 39.0 43.2 19.4‡***
AD, Alzheimer's disease; MD, mixed dementia.
* p-value < 0.05, ** p-value = 0.01, *** p-value = 0.001 between AD and MD
‡ p-value = 0.01 between MD and without dementia
Table 2: Pairwise comparisons between without dementia, AD and MD groups. These comparisons have been adjusted for age, 
gender, exercise, MMSE score and all four variables combined. Carnosinase activity is expressed as mean difference (SE)
Variable Carnosinase (µmol/ml/h)
Without dementia minus MD Without dementia minus AD AD minus MD
None 12.3 (6.4) -5.5 (5.2) 17.8 (6.7)**
Age 10.8 (6.0) -2.1 (5.1) 12.8 (6.5)‡
Gender 12.2 (6.4) -6.3 (5.5) 18.6 (6.9)**
Exercise 9.8 (6.1) -3.7 (5.0) 13.5 (6.5)*
MMSE score 1.7 (7.6)† -16.4 (7.2) 18.1 (5.9)**
Combined -1.9 (6.9) -14.7 (7.2) 12.8 (6.1)*
AD, Alzheimer's disease; MD, mixed dementia.
* p-value < 0.05, ** p-value = 0.01, † p-value = 0.06 between AD and MD
‡ p-value < 0.05 between MD and without dementiaBMC Neurology 2007, 7:38 http://www.biomedcentral.com/1471-2377/7/38
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A genetic basis for lower carnosinase activity is also possi-
ble. The gene for serum carnosinase is located on 18q22.3
[8]. A child with serum carnosinase deficiency was found
to have a deletion distal to 18q21.3 [39] and recently a
locus on chromosome 18 was identified for familial AD in
Caribbean Hispanics [40]. These two reports, along with a
study showing an association between the allelic variation
of this gene and carnosinase activity [41], lead to the spec-
ulation that lower carnosinase activity could be genetic. In
our study, patients with MD may have always had low car-
nosinase activity and thus susceptible to dementia. Down-
regulation of carnosinase mRNA is an alternative hypoth-
esis for lower carnosinase levels. Gene regulation has been
shown for the AD marker neural thread protein (AD7C-
NTP). It is up regulated in the brains and CSF of patients
with AD compared to controls [42].
In our study, carnosinase activity in MD was related to the
duration of dementia. This raises the possibility that car-
nosinase may have a role in monitoring the progression
and therapy of patients with MD. Furthermore, patients
treated with dementia medications had somewhat higher
carnosinase activities in both AD and MD groups (data
not shown). Regular exercise was also associated with
increased carnosinase activity and regular physical activity
has been associated with a decreased risk of vascular
dementia in women [43].
In contrast to other biomarkers for dementia, which are
measured in CSF, carnosinase is measured in the serum,
which is advantageous as venipuncture is far less invasive
than lumbar puncture. Carnosinase activity in CSF is
about 30-fold higher than the normal serum/CSF protein
ratio indicative of a predominantly brain-derived source
Carnosinase activity in patients who exercised regularly  (three or more times per week) compared to those who did  not exercise regularly Figure 4
Carnosinase activity in patients who exercised regu-
larly (three or more times per week) compared to 
those who did not exercise regularly. The mean carnos-
inase activity (µmol/ml/h) and 95% confidence intervals for 
the groups were: No = 31.4 (25.3 to 37.5), Yes = 44.6 (37.5 
to 51.7).
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Relationship between the duration of dementia and carnosi- nase activity in patients with MD (, n = 7) and AD (❍ , n =  12) Figure 2
Relationship between the duration of dementia and 
carnosinase activity in patients with MD (, n = 7) 
and AD (❍ , n = 12). Duration is the time from the first 
recorded date of diagnosis to the date of blood collection. 
Duration of dementia was significant for the MD group (--, r 
= -0.76, p = 0.05) but not for the AD group (----, r = -0.06, p 
= 0.86).
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Relationship between MMSE score and carnosinase activity  with MD (, n = 7) and AD (❍ , n = 13) Figure 3
Relationship between MMSE score and carnosinase 
activity with MD (, n = 7) and AD (❍ , n = 13). MMSE 
score were not related to carnosinase activity for the MD (--
, r = 0.55, p = 0.21) or the AD group (----, r = -0.19, p = 
0.54).
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of carnosinase in CSF [24]. Although studies have not
been done to determine the source of serum carnosinase,
carnosinase (CN1) is almost exclusively localized to brain
tissue.
It is important to comment on the method chosen to
measure carnosinase, as there are several methods
reported in the literature, making comparisons between
studies difficult. Optimization studies for measuring car-
nosinase activity were previously performed [33] showing
that maximum activity occurs at a pH of 8.5 with Cd2+ as
the metal ion cofactor and confirms those of Lenney et al.
[31]. Although Mn2+ is often used as the cofactor carnosi-
nase activity is about 4-fold lower compared to Cd2+. Car-
nosine, although not a specific substrate for carnosinase,
is preferred over homocarnosine as it is hydrolyzed more
rapidly. These conditions essentially prevent any activity
from the related cytosolic nonspecific dipeptidase (previ-
ously known as tissue carnosinase) from occurring [44].
Therefore, this assay method achieves high analytical spe-
cificity and sensitivity allowing small changes in activity
to be detected. These characteristics are beneficial not only
for diagnosis but also for monitoring changes in the dis-
ease state and treatment.
Since this study was exploratory in nature, designed to see
if serum carnosinase activity was altered in dementia, the
sample size was small and limited the use of multiple
regression analysis to adjust for potential confounding
variables. The potential for age, gender, medications and
other comorbidities to affect carnosinase activity cannot
be ruled out. However, apart from age, univariate analyses
for gender, MMSE score and exercise did not change the
results. There is limited data in the literature on the effect
of age or gender on carnosinase activity [31,33,45,46]. In
general, carnosinase activity is absent or low in newborns
and gradually increases until adulthood. Only two small
studies examined gender and found no difference [31,33].
This study, the first to report carnosinase activity in elderly
adults, did not show a difference in activity compared to
younger adult populations [31]. However, a larger group
of elderly persons is required to show whether there may
be an age or gender association with carnosinase activity.
In this study, there were a few patients with medical con-
ditions that have been associated with lower values of car-
nosinase activity (e.g., stroke, Parkinson's disease). No
patients in the AD and MD groups had any of these con-
ditions. The number of other medical conditions in any
group was too few to adjust for using regression analysis,
however, the AD group remained significantly different
from the MD group if any one of these exclusions was
made.
It is also possible that in the absence of post-mortem con-
firmation of diagnosis, some patients may have been mis-
classified. Diagnosis was made by mostly clinical
assessment and only nine of the twenty patients with
dementia had neuroimaging. Neuroimaging does not
necessarily improve diagnostic accuracy nor is it required
by published criteria for the diagnosis of dementia or AD
(though frequently included in the diagnostic evaluation)
[47]. For example, in a study of 501 patients evaluated for
dementia, 375 had a CT scan. In these 375 patients, 28%
of the diagnoses during life were incorrect when com-
pared with post mortem pathology. In those who did not
undergo CT scanning the diagnosis during life was incor-
rect only 18% of the time [48], Furthermore, CT scans
may both overestimate the presence of strokes [49] and
fail to identify them [50].
Carnosinase activity appears to play a role in dementia.
Lower carnosinase activity could be a biochemical
response for neuroprotection, a genetic variation in the
enzyme, or both. Further research is needed to determine
whether carnosinase fulfils the potential for a diagnostic
and disease-monitoring measure for dementia.
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